The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer. https://www.wired.com/story/new-melanoma-vaccine-reduces-risk-of-tumor-reoccurrence-by-over-40-percent/?utm_brand=wired-science&utm_campaign=aud-dev&utm_medium=social&utm_social-type=owned&utm_source=twitter-science